Physician profile

Natalie Allman

Neurology (Psychiatry & Neurology) · Philadelphia, PA

NPI 1548429137

$278.22

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$130.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Livanova USA, INC. $83.22 2024 Vns Therapy Sentiva Model 1000 Generator
Abbvie INC. $63.72 2021-2024 Qulipta
Allergan, INC. $43.61 2019-2021
Sk Life Science, INC. $18.94 2022
Otsuka America Pharmaceutical, INC. $18.19 2020
Ucb, INC. $18.11 2022
Amgen INC. $17.37 2020
Bausch Health US, LLC $15.06 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Natalie Allman

$278.22

in general payments reported 2019-2025

Years
2019-2024
Top company
Livanova USA, INC.

https://glasscript.com/doctor/378672/natalie-allman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.